Irradiation Blood and Blood Products in IBTO

Background:TA-GVHD is a rare, but usually fatal, complication of blood transfusions. This disease occurs when the lymphocytes of the donor enter the organs of a susceptible body. The TA-GVHD mortality rate is close to 100%.The main action in preventing TA-GVHD is gamma irradiation into blood and blood products. The elimination of leukocytes using current technology is inadequate for this purpose. Methods:In 2009, for the first time in Iranian Blood Transfusion Organization, the blood transfusion center of Tehran used a radiation device. During the years 2011-2016, other eight radiation devices were launched by other eight blood transfusion centers of IRAN. These 9centers provided irradiated blood and blood products for other neighboring provinces. Results:By the year 2016, we succeeded in launching 9radiation devices to meet the needs of all the provinces. Until now, the production of radiation products has reached 45,441 units of RBCIR and 160,446 units of PltIR. Discussion:Since, TA-GvHD is almost-always fatal, just the prevention is the effective action to avoid its occurring. Irradiation into blood and blood products - by deactivating the remaining lymphocytes - is the main axis and technology in such a situation.

کلیدواژه ها:

Irradiated blood and blood products ، Iranian Blood Transfusion ، TA-GvHD